Lyrica patient information








Pregabalin - Lyrica Medicine

11/15/2014
05:24 | Author: Chloe Allen

Lyrica patient information
Pregabalin - Lyrica Medicine

Read the information leaflet from inside the pack. You need to take pregabalin regularly. Do not stop taking it unless your doctor ls you to do.

Set your goal weight and track your progress along the way.

You’re not alone, reach out to thousands of patients.

Use this app to assess whether you may be depressed and make a tentative diagnosis of the severity of the depression.

Important : pregabalin has been associated with allergic-type symptoms in a few people. If you experience any difficulty breathing, or notice any swelling of your face, mouth, tongue or throat, you must contact your doctor for advice straightaway. If you experience any other symptoms which you think may be due to the medicine, speak with your doctor or pharmacist for further advice.

Help choosing the right treatment.

Check and improve your health.

Pregabalin is also prescribed to treat certain types of long-lasting pain caused by damage to nerves.

Comments (1)Read more



LYRICA (pregabalin) Capsules CV HCP Safety Info - PfizerPro

11/15/2014
03:12 | Author: Chloe Allen

Lyrica patient information
LYRICA (pregabalin) Capsules CV HCP Safety Info - PfizerPro

Important Safety Information. LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its other components. Angioedema and.

Pfizer.com| Pfizermedinfo.com.

In standard, preclinical in vivo lifetime carcinogenicity studies of LYRICA, an unexpectedly high incidence of hemangiosarcoma was identified in 2 different strains of mice. The clinical significance of this finding is unknown. In clinical studies across various patient populations comprising 6396 patient-years of exposure in patients > 12 years of age, new or worsening preexisting tumors were reported in 57 patients.

Patients with a history of drug or alcohol abuse may have a higher chance of misuse or abuse of LYRICA.

LYRICA (pregabalin) capsules is indicated for the management of:

In controlled studies, a higher proportion of patients treated with LYRICA reported blurred vision (7%) than did patients treated with placebo (2%), which resolved in a majority of cases with continued dosing.

Comments (2)Read more

Lyrica New FDA Drug Approval CenterWatch

11/15/2014
01:32 | Author: Jeremy Rodriguez

Lyrica patient information
Lyrica New FDA Drug Approval CenterWatch

Lyrica (pregabalin): For the treatment of pain associated with diabetic New approved drug details including side effects, uses and general information. It is also indicated as an adjunctive therapy for the treatment of adult patients with.

In addition, Lyrica is a Schedule V controlled substance. Studies of the drug in recreational users of sedative/hypnotic drugs indicated subjective psychoactive effects of a magnitude similar to the benzodiazepine diazepam. Roughly 4% of subjects reported eurphoria as an adverse event in trials, compared to 1% for placebo; some sub-populations reported euphoria rates as high as 12%. In addition, abrupt termination of treatment was associated with insomnia, nausea, headache and/or diarrhea. Patients receiving Lyrica should be monitored closely for evidence of dependence, misuse or abuse.

Drug Pipeline Resources Access the latest pipeline news from our industry-leading publications— The CenterWatch Monthly and CWWeekly.

Dizziness and somnolence occur regularly with Lyrica administration.

Comments (3)Read more